- Home
- KULR vs ABOS Comparison
KULR vs ABOS Comparison
Compare KULR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KULR | ABOS |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 165.4M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KULR | ABOS |
|---|---|---|
| Price | $3.83 | $2.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 2.7M | 337.2K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,274,028.00 | N/A |
| Revenue This Year | $123.93 | N/A |
| Revenue Next Year | $63.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $1.10 |
| 52 Week High | $7.49 | $3.60 |
Technical Indicators
Market Signals| Indicator | KULR | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 49.97 | 46.46 |
| Support Level | $2.93 | $2.14 |
| Resistance Level | $4.47 | $2.42 |
| Average True Range (ATR) | 0.44 | 0.14 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 17.45 | 34.91 |
Price Performance
Historical ComparisonAbout KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices. The Company operated two segments -EMP and Mining of Digital Assets.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.